C4 Therapeutics, Inc Investor Event Transcript, Nov 17, 2026
C4 Therapeutics, Inc. (CCCC)
C4 Therapeutics reported a 53% response rate for simsidamide at its 100 micrograms recommended Phase II dose in heavily pretreated multiple myeloma patients, with two MRD negative CRs. AI summary
Conference Transcript - CCCC 2026-11-17
Akash Tawari, Analyst — Jefferies
All righty. Good morning, everyone. It's still the morning. I run day two of our Jefferies Healthcare Conference, and it's really been, again, a joy to see everyone and so grateful for the attendance we see. My name is Akash Tawari. I am head of our biotech and pharma research efforts within Jefferies, and we have the management team for C4 Therapeutics. I think Andrew is going to start a bit with some prepared remarks, but then we'll get into Q&A. And again, I will just say this, we picked up coverage on this year. And when I think about established size of a market, When I, and I cover Bristol, when I talk to Bristol, and they will wax poetic about the importance of cell mods, and then when I think about smid cap companies that are pursuing the same strategy, the list is very short. I do think that is a very, very unique setup. And I do recommend you talk to them. But Andrew, I'll hand it off to you.
Speaker 0
Thank you, and that's a good introduction. Thanks for having us here. Before I begin, we'll be making four looking statements, and this is our disclaimer on that matter. C4 is a targeted protein degradation company, and we're really focused on really exploiting this novel modality, but our key focus right now in the clinic, at least, is on simsidamide and multiple myeloma, as well as building a sustainable pipeline. We've got some sitamide, which is our potential best-in-class cerebral unmodulating protein degrader of IKZF1 and 3. We are working to establish that as a backbone therapy in multiple myeloma. In addition, we have a discovery portfolio that is focused on inflammation, neuroinflammation, and neurodegeneration, invalidated pathways but against novel targets where degraders are important, as well as a number of platform collaborations that not only serve to expand the science of TPD, but really help bring in some non-dilutive capital as part of our strategy. And to that end, we are well capitalized. Our runway is through the end of 2028, which brings us through and beyond some important points. What I'll focus on in my short remarks is simsidamide. I think that's really where most of the discussion is, given the hybrid method of a presentation and Q&A. So, I think it's really important to start grounding in the mechanism of IKZF1-3 degradation. What is it, and what does it do? Way back when, when Celgene launched the IMIDS, no one actually knew what they did, and so they were developed in a way that I think was suboptimal in the sense that they're suboptimal by today's degradation standards. What's important about degrading IKZF1-3 is that it really leads to two outcomes. The first, you can see on the left panel, is it blocks the proliferation of plasma cells, which is really the root cause of multiple myeloma, so it has direct anti-myeloma activity, but also, importantly, it also activates the immune system. And that's going to be important when we think about the evolving landscape in multiple myeloma. And so what we know from lenalidomide and pomalidomide is that this mechanism really does serve as a backbone in multiple myeloma. It's used across all lines of treatment in multiple different combinations. But as I mentioned, lenalidomide and pomalidomide are really suboptimal degraders. They're not very potent, and they're frankly not very selective, and that's why you hear a lot about the toxicity profile. The evolving landscape in myeloma is really critical as we think about the future and future development, and one important aspect is immune-directed agents moving into earlier lines of treatment, both CAR-Ts and T-cell engagers, and we think simsidamide's profile actually sets it up very nicely to play in the new space, and I'll show you why we think that. So we ran a Phase I first-in-human study, and this is a one-slide summary of the data, but what's important is this study was done in the most heavily pretreated patient population in late-line therapy. You can see that 75% of patients were post-BCMA, but also post-CAR-T and T-cell engager therapy. And so that's important because those are patients who, while we think we're curing this disease with these immune-directed agents, There's still an unmet need, they're still showing up, and they've still enrolled in our study. And what's really dramatic is our safety profile is differentiated against BMS's next-gen degraders. You can see we've really had well-tolerated profile, and that's been coupled with, we think, really impressive antimyeloma activity at our recommended Phase II dose of 100 micrograms. And you heard me right, that's micrograms. We had a 53% response rate with two MRD negative CRs. And just to put that into context, in this late line, heavily pretreated population is something you don't normally see. But also importantly, we saw a robust response at a dose level one below our recommended phase two dose at 75 micrograms and an overall 36% response rate. So we think that this is what really shows it's a best-in-class. It really has class-leading efficacy, anti-myeloma activity, with a sort of, we think, best-in-class safety profile, and combined together, that positions it well. I mentioned the second MOA, and this slide illustrates that. You can see across all doses, and what we're showing here is representative of the wealth of data we have on immune cell activation. The first two left panels are demonstrating our ability to activate T cells, and the consequence of that, you see increased IL-2 cytokine production across really all the dose levels that we studied, which is critically important as we think about combination strategies in the future. So that leads to where the market opportunity is, and we think there's really two important opportunities. The first is, as these immune-directed agents move into earlier lines of treatment, patients are living longer, and that's great for patients, but these are not cures, despite what others in the field may start to talk about. And so we think what's happening there is two things. That's going to increase the population in the later line, fourth line plus, as those patients ultimately progress. And there is a need for an all-oral therapy for these patients. In addition, as we think about these agents moving into earlier lines of treatment, we think there's an opportunity to boost their activity and improve their duration by combining with an IKZF1 three to greater. And that's really where our development strategies focus. So currently, we have two ongoing studies. The first is a phase two single arm study we call momentum in late line patients, and that is positioned as a potential for an accelerated approval. We're also running a phase one B combination study with a bite of Pfizer's L-Renatumab, and that's in conjunction with a supply agreement with Pfizer. And that study is going to support a pivotal study with the same combination where we have another shot at accelerated approval with an MRD-CR, but importantly, we have a time-to-event endpoint that will serve as the confirmatory endpoint for both the accelerated approval in this second-line setting, but also for the late-line setting in the momentum study. And then lastly, we're running a combination study with jarotumumab and with carlofizumib as a way to establish broad combinability across the class because, as I mentioned, I think the profile that we demonstrated suggests that. Next year is setting up to be a really critical year. This year was one of execution, where we are aggressively enrolling our studies and generating data, but next year is really going to be data-rich. We expect a complete enrollment in the first quarter in the momentum study with an initial response rate data readout in the second half. And then in the middle of the year, we expect shared data from all doses and cohorts studied in the L-Renatumab combination study in the middle of 2027, as well as start that combination study with a CD38 and a proteasome inhibitor. And that's going to be pivotal in terms of setting up 2028, where, you know, with the If the data is supportive, we expect to submit by the end of the year for an NDA in that late-line setting and initiate that pivotal Phase III study in combination. So drilling into the details here, Lamentum is a 100-patient study using the 100-microgram recommended Phase II dose on a 14-day-on, 14-day-off schedule, and the primary endpoint is response rate. That trial is well underway, and we are confident that we're going to complete enrollment in the first quarter of next year. And then the phase 1b study, you know, we started that earlier this year, and we've progressed that nicely. We started off one dose level below the recommended phase 2 dose at 75 micrograms. That has been declared safe, and we've now both escalated to 100 micrograms, the recommended phase 2 dose, as well as expanded to get additional patient experience at 75 micrograms. I think what's notable about that is when you look at other drugs in the class, when they've tried to do similar combinations, they've had to de-escalate from their recommended phase two dose, almost two to three doses below that. In contrast, we've been able to establish safety at one dose level below and now working to establish safety at our recommended phase two dose, and I think that speaks to the safety profile and its broad potential for combinability really across the multimyeloma landscape. So, I'll end my prepare with Mark's, just reinforcing. IKZF-1-3 degradation is really, it's a foundational mechanism in treating myeloma across all different lines and multiple combinations. The profile we've established suggests that it's a best-in-class in terms of both the combination of safety and efficacy, and we're pursuing two distinct meaningful opportunities, both in the late line and in the second line or later, and we have a strategic development plan that is set up to capture those opportunities with a data They're rich 2027. So with that, we will open it up to questions. Thank you.
Akash Tawari, Analyst — Jefferies
I really appreciate the prepared remarks. And I want to actually start off with, obviously, you have two important readouts. You have the Pfizer bispecific, and then you get some of your fourth-line data next year. We also get some really critical data sets from Bristol, successor one, and then we also get some LBLC data, but the idea that this is going to move beyond just multiple myeloma. I want you, this is more conceptual, what do you feel like investors don't understand about the Selman opportunity that is just blaringly obvious for your team right now? And how do you think the Bristol readouts, and not just your own, change that narrative? Like, how soon are people going to realize, like, this is happening sooner than we think?
Speaker 0
So I'll answer first, and then I'll have Lynn comment. You know, I think what's challenging is no one's really focused on this mechanism, right? It's an old mechanism that was really, you know, as I mentioned, when Celgene launched lenalidomide and pomalidomide, nobody actually knew how they worked. Nobody knew they were degraders. They called them IMIDS, immunomodulatory drugs, but they didn't actually know how they worked, and so no one's really paid attention to the mechanism and how important it is. And so I think that's an important piece, because everyone's excited about the shiny new toys of CAR-T and T-cell engagers. And don't get me wrong, they're phenomenal drugs, and they've led to meaningful improvements in patient outcomes. But this is, as I mentioned, a critical mechanism for the disease, and I think people lose sight of that. And that's why maybe they don't understand, and they're not clear that, you know, are these optimized degraders better than... And certainly when we look at the data and we look at the safety profile, look at selectivity and the potency, we believe they are, and that's got to translate into the fact.
Len Reyno, Other
Yeah, I'm Len, I'm the chief medical officer. Obviously, I agree with that. I would, I would. Drill down a little bit on some of the concepts. So I think if you think about the space, and Bristol, obviously, leadership with IMITS, but they were developed pretty much as assets. They worked. They were given in combination. There was not a lot of thought of the mechanism of action because people didn't know what it was. At the same time that doing that, the space is overwhelmed with exciting new drugs with novel mechanisms of action. They put cell mods in clinic, and they put them in an asset replacement strategy to try to replace and maintain their franchise in first and second line. A laudable strategy, it probably would have done the same thing. While they're doing that, though, the excitement in the space has been on novel mechanisms of action and, in fact, has been on recently revisiting potent degraders and what they're actually doing. And so what we've been able to take advantage of, and I don't think people have fully processed it, to get back to your original very excellent question, is we've been able to... Say, hey, okay, Bristol has those plans. They're well-developed. Assume they're going to get multiple positive studies. They're going to get labels. They got their first one this summer. What can we do that actually is different and maximizes the unique features of semcinomine? And so what Andrew just outlined for you was that we have two clinical trials that between the two of them could lead to full approval in accomplishing from second line to late line. And that second-line approval, which is clearly most valuable, not married to yesterday's drugs, but married to today's drugs. In terms of the differentiation that we have, you know, we have the data that you just saw, but there's emerging data that actually helps sort of put a spotlight on it. Andrew pointed out correctly that we've cleared 75 micrograms in our first dose with bite. That's exciting. That was, like, extremely exciting to me because that 75 microgram dose level has a 40% response rate. Why does it matter? Because over and above any enhancement of the immune effect, if you can introduce a drug early in bite therapy that has its own 40% response rate, the chance that you can actually drive deeper, more meaningful MRD-CRs with that combination, I think can be inferred as a hypothesis that's strongly supported. The other piece of emerging data that's really helpful in distinguishing, I think, is what Andrew alluded to and showed you the data, that we have immune enhancement at all our clinically relevant doses. We couldn't distinguish a difference between those dose levels. At ASH coming up, you'll see some mesignamide data with a bite from Bristol, and they're interrogating 0.3 and 0.6. But one of the things that's in the abstract that's provocative to us because it's different is they point out that they don't get the immune enhancement at 0.3 and only get it at 0.6. Why does it matter? Again, in terms of broad-based strategies where you put a drug in phase three and expect that drug to be successful, a general rule in oncology that I think is held well and true is if you have a drug that has a broad mechanistic rationale over a range of doses With an effective safety profile, that drug's going to be a winner. So I think there is room for both companies, but our differentiated strategy, I think, sets us up well. And our differentiated strategy, to be really clear, is rooted in the primary molecular characteristics of the molecule and support it by really, really compelling data in every trial that we've done to date.
Akash Tawari, Analyst — Jefferies
Okay. Very helpful. And I want to hit on this more because, again, I think once people understand the concept. Then you can really apply to so many different phases of multimodal element, actually, frankly, beyond. So let's put a finer point on this. You've got momentum reading out mid-next year. This is the combo with the Pfizer-BCMA. You guys have shown, and we've seen with Bristol, yeah, you can get an 80-90% response rate, but that doesn't seem like what you're telling me to focus on. It's duration on treatment and deepening response, and so help us understand. Everyone expects the high response rate. What do you think the duration on treatment, the duration of response, could rival? Like, could we see that, you know, BCMA with the cell mod off the shelf, we have depth and duration of response that would rival any of the CAR-T regimens?
Len Reyno, Other
I think that's absolutely the goal, and I think that is well supported by our own data set. To your point, all of these combinations are going to have very high response rates. They're going to approach 100%. So you're going to be interested, even then, in differentiating on what proportion are CRs, what proportion are MRD negative CRs. But cautionary note, they're all going to be initially small data sets that are not powered for really true comparisons, but you're going to want to see more of that. I think that the promise that is well supported by the data is that you can get to a place where when a clinician is seeing a patient in a future state not that far off from now, that yes, there will be a choice to be made, and CAR-Ts currently have a lead, if you will, in the sense that people believe that all other things being equal, if you can give a CAR-T, you probably will get the highest response rate. There's some caveats there that people are missing, and the caveat there is if you look at the data in terms of the number of patients who are referred to a CAR-T center who actually get the CAR-T, when they talk about the high response rate of CAR-T, it's in the patients who actually get it. So you've lost some patients in the actual, they were referred for CAR-T, you never get CAR-T. So I think there's going to be a really compelling conversation space to talk with patients about, is CAR-T really better for you, and the value added with a bite combination with a drug like simcitamide. As we develop further, I think, you know, we'll have a better handle on what the delta is on long-term PFS, and I think speculating on how big that might be would be premature, but I would anticipate it will be real and will fit with an emerging practice pattern where a bite plus a drug like simcinomide, or with, I shouldn't say like, with simcinomide, will be the best choice.
Speaker 0
I think that's, I'll just add, that's important, because when you think about where myeloma is treated, 70 to 80 percent is treated in the community. They're not doing CAR-T in the community. You know, our latest data suggests that about 25 percent of patients who are eligible for CAR-T are actually getting it. So there's a real unmet need for deep, durable responses that can be administered in the community, and that's where we think, you know, a TCE plus simsidamide is really going to shine.
Akash Tawari, Analyst — Jefferies
Right. And just so that, you know, let's call our shot here. Okay, so how do you define when you're looking at the BCMA datasets that are coming up and the indication and setting that you're testing? So what's the investor bar for CAR-T durability response, CR, response rate as a whole that we should at least be thinking about? And let's say that you're even in that ballpark. Sounds like that's how you would define that as a significant win. So what are the bars that you're seeing?
Len Reyno, Other
So, the bars are moving constantly. I know. As we get more data. So, that would be the first thing. I think the second part of that, though, the response rate is going to need to be... Close to 100%. I think what's emerging in the literature right now on various trial modalities is that there is a baseline expectation in second line that your MRD negative CR rate should be in the order between 40 and 50%. So I think that's an important benchmark for planning, because in terms of planning a phase three trial, which is really, in some respects, the more important aspect of your question in terms of near-term investment, How do you plan a phase three trial that is the most cost-effective phase three trial, you're not overspending on it, that gets you to where you need to go as fast as possible? So we're doing that work right now, and the benchmarks we're looking at is, again, an MRD-negative rate of between 40% and 50%. And because you don't have true proof-of-concept data in terms of size, you have to pick a benchmark. You're going to have to get at least 15% or 20% higher than that. That will map in future to due course to a PFS benefit, but it's hard to know what that will be right now in the current environment. What I can tell you from a regulatory perspective, at least from a U.S. perspective, your MRD-negative CR rate will be compared within your trial. Okay, so you have to beat your standard arm. And likewise, your PFS benchmark will be within your trial. And then you'll get into the usual situation, which you'll see, you know, getting into ASH and post-ASH, where everybody's doing cross-trial comparisons, and, you know, they're useful to a point. But at some point, they don't really help you get where you need to go.
Akash Tawari, Analyst — Jefferies
I understand. Last point on this, and I respect that. I agree. I think it is 40 to 50%. That's a high bar, but it does seem like your team's not walking away from that. Duration on treatment, because that's where I feel like people miss on the BCMAs. They're not on the drug for a particularly long period of time, and the infections start to increase over time. Well, yeah, so let's talk about... But just to put a final point on that, do you feel like in combination with a cell mod, you would have a material improvement on the duration of response compared to just BCMAs by themselves, and how would you define that material improvement?
Len Reyno, Other
I, it would be getting way over my skis to try to define the material improvement. Do I think it's a reasonable hypothesis we can improve it? Yes, and here's why. We know that the labels for bites currently say that, you know, give the now and forever unless you're limited by toxicity or progression. We also know that thought leaders don't do that. That thought leaders, I'm not going to be thought leaders, clinicians don't do that. After a period of time, and if you did a survey, we just had an ad board with 11 top thought leaders. There was no consensus when they did it, but after at least a year, maybe two years, people are stopping the bite. I think, from a theoretical point of view, there'd be less incentive to stop the simcitamine, because it's easier to give. To your point about infection risk, I think that's obviously a really important one. It appears to me, my understanding of the data, that the bite infection risk, it's not so much it goes up over time, it just doesn't go down. It's a static, long-term, infective risk, which people are much, much better at managing that risk now than they were even two years ago. But it's still an issue. What we showed in our simsidamide data, now we'll get data with BITE, but what's really provocative in our simsidamide data is our risk of safety did not go up over time. That, in fact, the predicted changes in neutrophil counts, et cetera, early on in simsidamide were likely associated with the disease being out of control. And that long-term, we don't have patients coming off simsidamide for safety-related reasons. So I think there's a lot embedded at your very good question, but getting too far out over it, I think, would be...
Akash Tawari, Analyst — Jefferies
But it almost sounds like to me it's induction and then semisimide maintenance is really what you're going for.
Len Reyno, Other
Well, yeah, we have to be separate because we think that will happen organically with data, but we first need to get the drug approved, and likewise, that protocol will be specifically written with approval in mind.
Speaker 0
Yeah, and that's not the study we're doing, but you're right. As we hear KOLs talk more about fixed duration with the bites, which is driving people into deep MRD-negative CRs with a combination, and then, as I said, at the right time, there is no consensus removing the bite, but, as we've shown, simsidamide is very well taro-rided and very effective, and you can imagine a world where you're on a simsidamide maintenance therapy to maintain that deep response.
Akash Tawari, Analyst — Jefferies
I'm going to stick in a cheeky question at the end. This is one of the, I mean, it reminds me, like we had the Madrigal yesterday, and again, like people, Nash is not a market. Oh, it looks like it's a market. And then people, you know, the floodgates kind of open. I can't help but think with sell mods, it's this same dynamic where it's like, look, the first thing I hear when I talk to you, I feel like Seljoon was talking about this. Give me a break. And it takes a long time. It takes a lot of capital investment. It's hard to do as a smid cap company. I can't help but think, 2027, you get Successor 1, you get the head-to-head study against LEN in maintenance, and we get proof of concepts with both of your programs, too, and with a potential pivotal path. Do you think by the time we're having this discussion next year, The, you know, Bristol's excited, you're excited. Do you feel like from a strategic perspective, once we get some of those unlocks, the amount of pharma companies that would be interested in this target will materially increase? And what's been the gating factor so far?
Speaker 0
I mean, it's hard to predict, and I'm not going to sort of guess. Look, I do think this is a best-in-class asset with a critical modality in myeloma and should be part of your portfolio. You know, that said, our focus is on maximizing the value of syncytomide and executing the development plan that we've laid out that I just articulated, and that's really where we're focused. If someone in someone's boardroom decides to do something, that's beyond my control, and obviously, we will do the right thing for shareholders, but at this point, our focus is on executing the plan that I've outlined.
Akash Tawari, Analyst — Jefferies
Last question. I know we're over, but last question. The late line, pivotal data fourth line plus with Dex, there's been turnover with the agency, and I think when, and also what happened with Doge, you had some of the division heads leave, and what I've noticed is it doesn't mean that The bar gets, it's not like everything got easier or everything got worse. It really then reverts back to who's approving your drug and what biases maybe individuals within each review division have. So it's not a broad-based take. How confident are you with your team that, you know, you will have a path to Pivotal in the fourth line setting? And what is that bar that's been communicated with you by the FDA?
Speaker 0
Yes. So I think it's important to put in context how the FDA views single arm studies for potential for excited approval, right? They will always tell you. We prefer a randomized study, but we recognize there are certain scenarios where that's not possible, and so they will certainly look at it, but they won't give you that determination until you show up with data and have that discussion, and so it's premature to sort of say where we are, but the other important component is it's going to be judged in the context of the then-current standard of care in that setting when we show up for the data. So it really depends on that, and then to your point, on who's there and who we're speaking to.
Akash Tawari, Analyst — Jefferies
Has that changed at all, or it's the same team?
Speaker 0
No, it's changed. It's changed. The division director that we've been speaking with left, and there's a transition.
Akash Tawari, Analyst — Jefferies
Okay, and, uh, okay, we gotta go.